NCT07204379

Brief Summary

after 2 visit endodontics treatment, the analgesic efficacy of three different medications will be evaluated.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P75+ for early_phase_1

Timeline
Completed

Started Jan 2023

Shorter than P25 for early_phase_1

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2023

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 15, 2023

Completed
16 days until next milestone

Study Completion

Last participant's last visit for all outcomes

July 31, 2023

Completed
2.2 years until next milestone

First Submitted

Initial submission to the registry

September 25, 2025

Completed
7 days until next milestone

First Posted

Study publicly available on registry

October 2, 2025

Completed
Last Updated

October 2, 2025

Status Verified

September 1, 2025

Enrollment Period

7 months

First QC Date

September 25, 2025

Last Update Submit

September 25, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Post operative pain

    Post operative pain to be measured/evaluated in patients undergoing root canal therapy using visual analog scale (VAS). This is a numeric scale with readings 0-10. with 0 indicating no pain, 1-3 indicating mild pain, 4-6 indicating moderate pain, and 7-10 indicating severe pain.

    6 hours - 72 hours

Study Arms (4)

Placebo group

PLACEBO COMPARATOR

this group to be administered placebo medication (multi-vitamins)

Other: No intervention?placebo

Novafen group

ACTIVE COMPARATOR

this group to be administered Novafen medication

Drug: Novafen

Tramadol group

ACTIVE COMPARATOR

this group to be administered Tramadol Medication

Drug: Tramadol

Naproxen group

ACTIVE COMPARATOR

this group to be administered Naproxen medication

Drug: Naproxen

Interventions

Novafen analgesic medication to be administered as pain painkiller in one group of patients undergoing root canal therapy

Novafen group

Tramadol analgesic medication to be administered as pain painkiller in one group of patients undergoing root canal therapy

Tramadol group

naproxen analgesic medication to be administered as pain painkiller in one group of patients undergoing root canal therapy

Naproxen group

multivitamins to be administered in this group

Placebo group

Eligibility Criteria

Age16 Years - 65 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Patients were aged between 20 and 60 years 2. Patients with moderate to severe spontaneous pain associated with irreversible pulpitis in single-rooted 3- premolars or anterior teeth with no clinical or radiographic signs or symptoms of acute or chronic apical periodontitis

You may not qualify if:

  • Systemic disease
  • Pregnant womens
  • History of taking analgesics in previous 12 hrs or other drugs prior to presenting for treatment.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

AFID

Rawalpindi, Punjab Province, 54000, Pakistan

Location

MeSH Terms

Conditions

Pain, Postoperative

Interventions

L 5409709TramadolNaproxen

Condition Hierarchy (Ancestors)

Postoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and SymptomsPainNeurologic ManifestationsSigns and Symptoms

Intervention Hierarchy (Ancestors)

CyclohexanolsHexanolsFatty AlcoholsAlcoholsOrganic ChemicalsDimethylaminesMethylaminesAminesLipidsNaphthaleneacetic AcidsNaphthalenesPolycyclic Aromatic HydrocarbonsHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsPolycyclic Compounds

Study Design

Study Type
interventional
Phase
early phase 1
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Model Details: patients to be divided into 4 equal groups and different drugs to be administered amongst each group and efficacy evaluated afterwards.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal investigator

Study Record Dates

First Submitted

September 25, 2025

First Posted

October 2, 2025

Study Start

January 1, 2023

Primary Completion

July 15, 2023

Study Completion

July 31, 2023

Last Updated

October 2, 2025

Record last verified: 2025-09

Data Sharing

IPD Sharing
Will not share

Locations